The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A
Brunner, H. G., Nelen, M., Breakefield, X. O., Ropers, H. H., & van Oost, B. A. (1993) · Science · doi:10.1126/science.8211186 · Cited by 1,644
Some observations upon a new inhibitor of monoamine oxidase in brain tissue
Johnston, J. P. (1968) · Biochemical Pharmacology · doi:10.1016/0006-2952(68)90066-x · Cited by 1,578
The therapeutic potential of monoamine oxidase inhibitors
Youdim, M. B. H., Edmondson, D., & Tipton, K. F. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1883 · Cited by 1,363
Tyrosine hydroxylase and regulation of dopamine synthesis
Daubner, S. C., Le, T., & Wang, S. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.12.017 · Cited by 1,092
Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine
Eisenhofer, G., Kopin, I. J., & Goldstein, D. S. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.1 · Cited by 1,072
Heikkila, R. E., Manzino, L., Cabbat, F. S., & Duvoisin, R. C. (1984) · Nature · doi:10.1038/311467a0 · Cited by 1,010
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders
Binda, C., Newton-Vinson, P., Hubálek, F., Edmondson, D. E., & Mattevi, A. (2002) · Nature Structural Biology · doi:10.1038/nsb732 · Cited by 644
Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641
Monoamine oxidase inactivation: from pathophysiology to therapeutics
Bortolato, M., Chen, K., & Shih, J. C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.06.002 · Cited by 634
Binda, C., Wang, J., Pisani, L., Caccia, C., Carotti, A., Salvati, P., Edmondson, D. E., & Mattevi, A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070677y · Cited by 607
Meyer, J. H., Ginovart, N., Boovariwala, A., Sagrati, S., Hussey, D., Garcia, A., Young, T., Praschak-Rieder, N., Wilson, A. A., & Houle, S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1209 · Cited by 585
Catecholamine metabolism: basic aspects and clinical significance.
Kopin, I. J. (1985) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06859-0 · Cited by 582
Pargyline Prevents MPTP-Induced Parkinsonism in Primates
Langston, J. W., Irwin, I., Langston, E. B., & Forno, L. S. (1984) · Science · doi:10.1126/science.6332378 · Cited by 581
Some puzzling pharmacological effects of monoamine oxidase inhibitors.
Knoll, J. E., & Magyar, K. (1972) · PubMed · Cited by 560
De Colibus, L., Li, M., Binda, C., Lustig, A., Edmondson, D. E., & Mattevi, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505975102 · Cited by 527
Artigas, F. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030084009 · Cited by 510
Monoamine oxidase : structure, function, and altered functions
Singer, T. P., Korff, R. W. V., & Murphy, D. L. (1979) · Academic Press eBooks · Cited by 482
Histone H3 Lysine 4 Demethylation Is a Target of Nonselective Antidepressive Medications
Lee, M. G., Wynder, C., Schmidt, D. M., McCafferty, D. G., & Shiekhattar, R. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.05.004 · Cited by 438
Brain monoamine oxidase A inhibition in cigarette smokers
Fowler, J. S., Volkow, N. D., Wang, G.-J., Pappas, N., Logan, J., Shea, C., Alexoff, D., MacGregor, R. R., Schlyer, D. J., Zezulkova, I., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14065 · Cited by 423
Structure and Mechanism of Monoamine Oxidase
Edmondson, D. E., Mattevi, A., Binda, C., Li, M., & Hubalek, F. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364784 · Cited by 368
Birkmayer, W., Riederer, P., Youdim, M. B. H., & Linauer, W. (1975) · Journal of Neural Transmission · doi:10.1007/bf01253131 · Cited by 363
Youdim, M. B. H., Gross, A., & Finberg, J. P. M. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703826 · Cited by 342
Self-citationEffects ofl-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats
Abercrombie, E. D., Bonatz, A. E., & Zigmond, M. J. (1990) · Brain Research · doi:10.1016/0006-8993(90)91318-b · Cited by 332
Bambico, F. R., Katz, N., Debonnel, G., & Gobbi, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-07.2007 · Cited by 325
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Presynaptic Recording of Quanta from Midbrain Dopamine Neurons and Modulation of the Quantal Size
Pothos, E. N., Davila, V., & Sulzer, D. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-11-04106.1998 · Cited by 320
Bodkin, J. A., & Amsterdam, J. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1869 · Cited by 318
Williams, C. H. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90626-1 · Cited by 314
trans-2-Phenylcyclopropylamine Is a Mechanism-Based Inactivator of the Histone Demethylase LSD1
Schmidt, D. M. Z., & McCafferty, D. G. (2007) · Biochemistry · doi:10.1021/bi0618621 · Cited by 307
The serotonin syndrome and its treatment
Gillman, P. K. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300111 · Cited by 306
Molecular and Mechanistic Properties of the Membrane-Bound Mitochondrial Monoamine Oxidases
Edmondson, D. E., Binda, C., Wang, J., Upadhyay, A. K., & Mattevi, A. (2009) · Biochemistry · doi:10.1021/bi900413g · Cited by 300
IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASE
Birkmayer, W., Riederer, P., Ambrozi, L., & Youdim, M. B. H. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91940-7 · Cited by 297
Deprenyl is metabolized to methamphetamine and amphetamine in man.
Reynolds, G., Elsworth, J., Blau, K., Sandler, M., Lees, A., & Stern, G. (1978) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1978.tb00883.x · Cited by 285
Hare, M. L. C. (1928) · Biochemical Journal · doi:10.1042/bj0220968 · Cited by 283
Pathogenic role of glial cells in Parkinson's disease
Teismann, P., Tieu, K., Cohen, O., Choi, D., Wu, D. C., Marks, D., Vila, M., Jackson‐Lewis, V., & Przedborski, S. (2003) · Movement Disorders · doi:10.1002/mds.10332 · Cited by 275
Griebel, G., Stemmelin, J., & Scatton, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.032 · Cited by 253
A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action
Gillman, P. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.016 · Cited by 248
Brain Monoamine Oxidase A Activity Predicts Trait Aggression
Alia-Klein, N., Goldstein, R. Z., Kriplani, A., Logan, J., Tomasi, D., Williams, B., Telang, F., Shumay, E., Biegon, A., Craig, I. W., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0925-08.2008 · Cited by 245
Yang, M., Culhane, J. C., Szewczuk, L. M., Jalili, P., Ball, H. L., Machius, M., Cole, P. A., & Yu, H. (2007) · Biochemistry · doi:10.1021/bi700664y · Cited by 234
O'Carroll, A.-M., Fowler, C. J., Phillips, J. P., Tobbia, I., & Tipton, K. F. (1983) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00500765 · Cited by 230
Elevated Brain Serotonin Turnover in Patients With Depression: Effect of Genotype and Therapy
Barton, D. A., Esler, M. D., Dawood, T., Lambert, E. A., Haikerwal, D., Brenchley, C., Socratous, F., Hastings, J., Guo, L., Wiesner, G., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.11 · Cited by 220
MAO-inhibitors in Parkinson's Disease
Riederer, P., & Laux, G. (2011) · Experimental Neurobiology · doi:10.5607/en.2011.20.1.1 · Cited by 215
Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies
Tong, J., Meyer, J. H., Furukawa, Y., Boileau, I., Chang, L.-J., Wilson, A. A., & Houle, S. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.19 · Cited by 213
Rascol, O., Fitzer-Attas, C. J., Hauser, R., Jankovic, J., Lang, A., Langston, J. W., Melamed, E., Poewe, W., Stocchi, F., Tolosa, E., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70073-4 · Cited by 212
Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B
Edmondson, D. E., Binda, C., & Mattevi, A. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.05.006 · Cited by 203
Structure of Rat Monoamine Oxidase A and Its Specific Recognitions for Substrates and Inhibitors
Ma, J., Yoshimura, M., Yamashita, E., Nakagawa, A., Ito, A., & Tsukihara, T. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.032 · Cited by 200
Da Prada, M., Kettler, R., Keller, H. H., Burkard, W. P., Muggli-Maniglio, D., & Haefely, W. E. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23665-5 · Cited by 199
Safinamide: From molecular targets to a new anti-Parkinson drug
Caccia, C., Maj, R., Calabresi, M., Maestroni, S., Faravelli, L., Curatolo, L., Salvati, P., & Fariello, R. G. (2006) · Neurology · doi:10.1212/wnl.67.7_suppl_2.s18 · Cited by 195
Regulation of Quantal Size by Presynaptic Mechanisms
Sulzer, D., & Pothos, E. N. (2000) · Reviews in the Neurosciences · doi:10.1515/revneuro.2000.11.2-3.159 · Cited by 184
Mann, J. J. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810010047007 · Cited by 178
Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
Weinreb, O., Amit, T., Bar-Am, O., & Youdim, M. B. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.008 · Cited by 171
Lenders, J. W. M., Eisenhofer, G., Abeling, N. G. G. M., Berger, W., Murphy, D. L., Konings, C. H., Wagemakers, L. M., Kopin, I. J., Karoum, F., Gennip, A. H., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118492 · Cited by 170
Tatton, W. G. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.171s · Cited by 166
Carlile, G. W., Chalmers-Redman, R. M. E., Tatton, N. A., Pong, A., Borden, K. L. B., & Tatton, W. G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26436-1 · Cited by 164
Lotufo-Neto, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00075-x · Cited by 159
Guillem, K., Vouillac, C., Azar, M. R., Parsons, L. H., Koob, G. F., Cador, M., & Stinus, L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2139-05.2005 · Cited by 158
Neuroprotection by propargylamines in Parkinson's disease
Maruyama, W., Akao, Y., Carrillo, M.-C., Kitani, K., Youdium, M. B. H., & Naoi, M. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00221-0 · Cited by 154
Amsterdam, J. D. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0216 · Cited by 147
Butcher, S. P., Fairbrother, I. S., Kelly, J. S., & Arbuthnott, G. W. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb04587.x · Cited by 140
Preferential deamination of dopamine by an A type monoamine oxidase in rat brain
Waldmeier, P. C., Delini‐Stula, A., & Ma�tre, L. (1976) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00506483 · Cited by 139
New directions in monoamine oxidase A and B selective inhibitors and substrates
Youdim, M. B. H., & Finberg, J. P. M. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90471-g · Cited by 139
Self-citationThomas, D. M., Francescutti, D. M., & Kuhn, D. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05155.x · Cited by 133
Lamensdorf, I., Youdim, M. B. H., & Finberg, J. P. M. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67041532.x · Cited by 132
Self-citationSerotonin-Containing Neurons in Brain: Depression of Firing by Monoamine Oxidase Inhibitors
Aghajanian, G. K., Graham, A. W., & Sheard, M. H. (1970) · Science · doi:10.1126/science.169.3950.1100 · Cited by 131
Selective inhibitors of monoamine oxidase type B and the “cheese effect”
Finberg, J. P. M., & Gillman, P. K. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00009-1 · Cited by 123
Self-citationYoudim, M. B. H. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.1 · Cited by 121
Biochemical post-mortem findings in depressed patients
Birkmayer, W., & Riederer, P. F. (1975) · Journal of Neural Transmission · doi:10.1007/bf01663627 · Cited by 118
Brain dopamine and serotonin differ in regulation and its consequences
Hashemi, P., Dankoski, E. C., Lama, R., Wood, K. M., Takmakov, P. A., & Wightman, R. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201547109 · Cited by 115
Volz, H., & Gleiter, C. H. (1998) · Drugs & Aging · doi:10.2165/00002512-199813050-00002 · Cited by 110
A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders
Witkin, J. M., Tzavara, E. T., Davis, R. J., Li, X., & Nomikos, G. G. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.10.006 · Cited by 110
Celada, P., & Artigas, F. (1993) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00166940 · Cited by 107
Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer.
Knoll, J. E., Ecsery, Z., Kelemen, K., NIEVEL, J. G., & Knoll, B. (1965) · PubMed · Cited by 107
Transcriptional regulation and multiple functions of MAO genes
Shih, J. C., Wu, J. B., & Chen, K. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0562-9 · Cited by 106
Przuntek, H., Conrad, B., DICHGANS, J., Kraus, P. H., Krauseneck, P., Pergande, G., Rinne, U. K., Schimrigk, К., Schnitker, J., & Vogel, H. P. (1999) · European Journal of Neurology · doi:10.1111/j.1468-1331.1999.tb00007.x · Cited by 106
Milczek, E. M., Binda, C., Rovida, S., Mattevi, A., & Edmondson, D. E. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08386.x · Cited by 105
Vitalis, T., Fouquet, C., Alvarez, C., Seif, I., Price, D. J., Gaspar, P., & Cases, O. (2002) · The Journal of Comparative Neurology · doi:10.1002/cne.10093 · Cited by 103
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.007 · Cited by 102
Oxidative Stress and Free Radical Damage in Neurology
Gadoth, N., & Goebel, H. H. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-514-9 · Cited by 101
Behavioral Disinhibition and Reduced Anxiety-like Behaviors in Monoamine Oxidase B-Deficient Mice
Bortolato, M., Godar, S. C., Davarian, S., Chen, K., & Shih, J. C. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.118 · Cited by 99
Monoamine Oxidase Inhibitors Allow Locomotor and Rewarding Responses to Nicotine
Villégier, A., Salomon, L., Granon, S., Changeux, J., Belluzzi, J. D., Leslie, F. M., & Tassin, J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300987 · Cited by 95
Gallardo‐Pujol, D., Pueyo, A. A., & Maydeu‐Olivares, A. (2012) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2012.00868.x · Cited by 89
Selegiline Transdermal System for the Treatment of Major Depressive Disorder
Feiger, A. D., Rickels, K., Rynn, M. A., ZIMBROFF, D. L., & Robinson, D. S. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0905 · Cited by 88
Monoamine Oxidase-B Mediates Ecstasy-Induced Neurotoxic Effects to Adolescent Rat Brain Mitochondria
Alves, E., Summavielle, T., Alves, C. J., GOMES‐DA‐SILVA, J., Barata, J. C., Fernandes, E. G. R., Bastos, M. D. L., Ferreira, M. A., & Carvalho, F. D. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2645-07.2007 · Cited by 86
Striatal Dopamine Metabolism in Monoamine Oxidase B‐Deficient Mice : A Brain Dialysis Study
Fornai, F., Chen, K., Giorgi, F. S., Gesi, M., Alessandri, M., & Shih, J. C. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732434.x · Cited by 84
Westlund, K. N., Krakower, T. J., Kwan, S., et al. (1993) · Brain Research · doi:10.1016/0006-8993(93)91664-e · Cited by 84
Monte, D. A. D., DeLanney, L. E., Irwin, I., Royland, J. E., Chan, P., Jakowec, M. W., & Langston, J. W. (1996) · Brain Research · doi:10.1016/0006-8993(96)00761-5 · Cited by 82
Baker, G. B., Coutts, R. T., McKenna, K. F., & Sherry-McKenna, R. L. (1992) · PubMed Central · Cited by 75
Hill, M. N., Ho, W.-S. V., Hillard, C. J., & Gorzalka, B. B. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0131-7 · Cited by 75
Ginovart, N., Wilson, A. A., Meyer, J. H., Hussey, D. F., & Houle, S. (2002) · Synapse · doi:10.1002/syn.10155 · Cited by 75
López-Real, A. M., Rodríguez‐Pallares, J., Guerra, M. J., & Labandeira-García, J. L. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02291-1 · Cited by 75
Gillman, P. K. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820469ea · Cited by 74
Upadhyay, A. K., Borbat, P. P., Wang, J., Freed, J. H., & Edmondson, D. E. (2008) · Biochemistry · doi:10.1021/bi7021377 · Cited by 74
Guillem, K., Vouillac‐Mendoza, C., Azar, M. R., Parsons, L. H., Koob, G. F., Cador, M., & Stinus, L. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05217.x · Cited by 74
Finberg, J. P. M., & Youdim, M. B. H. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00216-2 · Cited by 72
Self-citationNaoi, M., & Maruyama, W. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.68 · Cited by 72
Pérez, V., Puigdemont, D., Gilaberte, I., Álvarez, E., & Artigas, F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00008 · Cited by 70
Jenner, P. (2008) · Movement Disorders · doi:10.1002/mds.22022 · Cited by 69
Maintenance of Brain Monoamine Oxidase B Inhibition in Smokers After Overnight Cigarette Abstinence
Fowler, J. S., Wang, G., Volkow, N. D., Franceschi, D., Logan, J., Pappas, N. R., Shea, C. E., MacGregor, R. R., & Garza, V. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1864 · Cited by 68
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease
Jenner, P. G. (2004) · Neurology · doi:10.1212/wnl.63.7_suppl_2.s13 · Cited by 64
Psychopharmacology: Part 1 preclinical psychopharmacology
(1983) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(83)90502-3 · Cited by 64
Shioda, K., Nisijima, K., Yoshino, T., & Kato, S. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.01.013 · Cited by 63
Cenci, M. A., Ohlin, K. E., & Ottosson, D. R. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70782-5 · Cited by 63
Monoamine oxidase inhibitor antidepressants
Youdim, M. B. H., & Finberg, J. P. M. (1985) · Elsevier eBooks · doi:10.1016/b978-0-444-90350-1.50008-8 · Cited by 63
Self-citationElkashef, A. M., Fudala, P. J., Gorgon, L., Li, S.-H., Kahn, R., Chiang, N., Vocci, F. J., Collins, J., Jones, K. M., Boardman, K., et al. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.010 · Cited by 60
Finberg, J. P. M., Wang, J., Goldstein, D. S., Kopin, I. J., & Bankiewicz, K. S. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65031213.x · Cited by 59
Self-citationDenney, R. M., & Denney, C. B. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90050-6 · Cited by 59
Lights and Shadows on Monoamine Oxidase Inhibition in Neuroprotective Pharmacological Therapies
Binda, C., Milczek, E. M., Bonivento, D., Wang, J., Mattevi, A., & Edmondson, D. E. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611798184355 · Cited by 59
Fowler, J. S., Logan, J., Azzaro, A. J., Fielding, R. M., Zhu, W., Poshusta, A. K., BURCH, D. J., Brand, B., Free, J., Asgharnejad, M., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.167 · Cited by 58
Czoty, P. W., Justice, J. B., & Howell, L. (2000) · Psychopharmacology · doi:10.1007/s002130050054 · Cited by 57
Mandel, S. A., Sagi, Y., & Amit, T. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9351-8 · Cited by 53
Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression
Lecrubier, Y., & Guelfi, J. D. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05319.x · Cited by 53
Iurlo, M., Leone, M. G., Schilström, B., Linnér, L., Nomikos, G. G., Hertel, P., Silvestrini, B., & Svensson, T. (2001) · Psychopharmacology · doi:10.1007/s002130100879 · Cited by 49
Effects of single and chronic treatment with tranylcypromine on extracellular serotonin in rat brain
Ferrer, A., & Artigas, F. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90717-x · Cited by 48
Safinamide in the treatment of Parkinson's disease
Schapira, A. H. V. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.511612 · Cited by 48
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease
Weinreb, O., Amit, T., Riederer, P. F., Youdim, M. B. H., & Mandel, S. A. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00007-8 · Cited by 47
Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase
Castagnoli, K., Steyn, S. J., Magnin, G., der Schyf, C. J. V., Fourie, I., Khalil, A. A., & Castagnoli, N. (2002) · Neurotoxicity Research · doi:10.1080/10298420290015854 · Cited by 47
Azzaro, A. J., VanDenBerg, C. M., Blob, L. F., Kemper, E. M., Sharoky, M., Oren, D. A., & Campbell, B. J. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006289852 · Cited by 45
Thomas, D. M., Francescutti, D. M., & Kuhn, D. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06094.x · Cited by 43
Caille, D., Bergis, O. E., Fankhauser, C., Gardes, A., Adam, R., Charieras, T., Grosset, A., Rovei, V., & JARREAU, F. ‐. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12818-8 · Cited by 41
Adli, M., Pilhatsch, M., Bauer, M., Köberle, U., Ricken, R., Janssen, G., Ulrich, S., & Bschor, T. (2008) · Pharmacopsychiatry · doi:10.1055/s-0028-1083819 · Cited by 41
Yoneda, F. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00002-5 · Cited by 41
Efficacy and Tolerability of Tranylcypromine Versus Phenelzine
Birkenhäger, T. K., van den Broek, W. W., Mulder, P. G. H., Bruijn, J. A., & Moleman, P. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1110 · Cited by 41
Arai, R., Karasawa, N., Kurokawa, K., Kanai, H., Horiike, K., & Itô, A. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00351-2 · Cited by 40
Slotkin, T. A., Seidler, F. J., & Ritchie, J. (1998) · Brain Research Bulletin · doi:10.1016/s0361-9230(98)00111-7 · Cited by 39
Metabolism and Pharmacokinetics of Phenelzine
Robinson, D. S., Cooper, T. B., Jindal, S. P., CORCELLA, J., & LUTZ, T. (1985) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198505060-00005 · Cited by 39
Absence of acute cocaine interactions with the MAO-B inhibitor selegiline
Haberny, K. A., WALSH, S. L., Ginn, D. H., Wilkins, J. N., Garner, J. E., Setoda, D., & Bigelow, G. E. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01137-n · Cited by 39
Sader-Mazbar, O., Loboda, Y. V., Rabey, M. J., & Finberg, J. P. M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12349 · Cited by 37
Self-citationWeinstock, M., Gorodetsky, E. K., Wang, R. H., Gross, A., Weinreb, O., & Youdim, M. B. H. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00176-4 · Cited by 37
Kitanaka, N., Kitanaka, J., & Takemura, M. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.09.026 · Cited by 36
Chronic intermittent L ‐DOPA treatment induces changes in dopamine release
Lundblad, M., af Bjerkén, S., Cenci, M. A., Pomerleau, F., Gerhardt, G. A., & Strömberg, I. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05848.x · Cited by 35
Yu, P. H., & Tipton, K. F. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90522-4 · Cited by 34
Lanteri, C., Hernàndez-Vallejo, S. J., Salomon, L., Doucet, E. L., Godeheu, G., Torrens, Y., Houades, V., & Tassin, J. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3315-08.2009 · Cited by 34
Hassanzadeh, P., & Rahimpour, S. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2120-4 · Cited by 34
Lundquist, P., Roman, M., Syvänen, S., Hartvig, P., Blomquist, G., Hammarlund‐Udenaes, M., & Långström, B. (2007) · Synapse · doi:10.1002/syn.20382 · Cited by 32
Adverse Syndromes and Psychiatric Drugs
(2004) · Oxford University Press eBooks · doi:10.1093/med/9780198527480.001.0001 · Cited by 31
Ordway, G. A., Farley, J. T., Dilley, G. E., Overholser, J. C., Meltzer, H. Y., Balraj, E. K., Stockmeier, C. A., & Klimek, V. (1999) · Brain Research · doi:10.1016/s0006-8993(99)02043-0 · Cited by 31
Löhle, M., & Reichmann, H. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-112 · Cited by 30
Modification of vesicular dopamine and norepinephrine by mono amine oxidase inhibitors
Buu, N. T. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90318-3 · Cited by 28
Glezer, S., & Finberg, J. P. M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01906-x · Cited by 28
Self-citationGuillem, K., Vouillac‐Mendoza, C., Koob, G. F., Cador, M., & Stinus, L. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.029 · Cited by 28
Aluf, Y., Vaya, J., Khatib, S., Loboda, Y., & Finberg, J. P. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.08.023 · Cited by 27
Self-citationLotfipour, S., Arnold, M. M., Hogenkamp, D. J., Gee, K. W., Belluzzi, J. D., & Leslie, F. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.03.007 · Cited by 26
Villégier, A., Salomon, L., Blanc, G., Godeheu, G., Glowinski, J., & Tassin, J. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05011.x · Cited by 25
Monoamine oxidases: from brain maps to physiology and transgenics to pathophysiology
Richards, J. G., Saura, J., Luque, J. M., Cesura, A. M., Gottowik, J., Malherbe, P., Borroni, E., & Gray, J. A. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6499-0_17 · Cited by 25
Selegiline potentiates cocaine‐induced increases in rodent nucleus accumbens dopamine
Schiffer, W. K., Azmoodeh, M., Gerasimov, M. R., Volkow, N. D., Fowler, J. S., & Dewey, S. L. (2003) · Synapse · doi:10.1002/syn.10183 · Cited by 20
Monoamine Oxidase Inhibitors Revisited: What You Should Know
Goldberg, J. F., & Thase, M. E. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12ac08299 · Cited by 19
Pepper, J., Baumann, M. H., AYESTAS, M. A., & Rothman, R. B. (2001) · Molecular Brain Research · doi:10.1016/s0169-328x(01)00013-4 · Cited by 19
Oxidative Stress in Parkinson's Disease
Vaya, J., Aluf, Y., & Finberg, J. P. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-514-9_12 · Cited by 16
Self-citationAzzaro, A. J., VanDenBerg, C. M., Ziemniak, J. A., Kemper, E. M., Blob, L. F., & Campbell, B. J. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007302950 · Cited by 16
Kitanaka, N., Kitanaka, J., Watabe, K., & Takemura, M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.11.058 · Cited by 15
Finberg, J. P. M., Gross, A., Bar‐Am, O., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706908 · Cited by 14
Self-citationMatveychuk, D., Nunes, E. A., Ullah, N., Velázquez‐Martínez, C. A., MacKenzie, E. M., & Baker, G. B. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-0978-0 · Cited by 12
Assareh, N., ElBatsh, M. M., Marsden, C. A., & Kendall, D. A. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.017 · Cited by 12
Bech, P., Stage, K. B., Larsen, J. K., Vestergaard, P., & Gram, L. F. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.02.011 · Cited by 7
Coutts, R. T., Mozayani, A., Danielson, T. J., et al. (1991) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600800812 · Cited by 4
NOT ALL MONOAMINE OXIDASE INHIBITORS ARE CREATED EQUAL
Stewart, J. T. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01382.x · Cited by 2
Cited by
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
Finberg, J. P. M., & Rabey, J. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00340 · Cited by 432
Self-citationSerotonin in Animal Cognition and Behavior
Bacqué-Cazenave, J., Bharatiya, R., Barrière, G., Delbecque, J.-P., Bouguiyoud, N., Di Giovanni, G., Cattaert, D., & De Deurwaerdère, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051649 · Cited by 340
Li, Q., Yang, H., Chen, Y., & Sun, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.062 · Cited by 322
Ramsay, R., & Tipton, K. (2017) · Molecules · doi:10.3390/molecules22071192 · Cited by 258
Gillman, P. K. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1932-y · Cited by 255
Metadata
- Authors
- Finberg, J. P. M.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 143
- Issue
- 2
- Pages
- 133-152
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2063087688
- Cited by
- 257
- References
- 159
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.